Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis

Fig. 4

Prognosis of AML patients with TET2 mutation according to ELN risk-stratification. a pooled ORs and 95%CI for the CR rate in patients with ELN favorable-risk cytogenetics(OR 0.460; P = 0.011). b pooled HRs for OS in patients with ELN favorable-risk cytogenetics(HR 2.034; P < 0.001). c pooled HRs and 95%CI for EFS in patients with ELN favorable-risk cytogenetics(HR 2.140; P < 0.001). d pooled HRs and 95%CI for EFS in patients with ELN intermediate-risk cytogenetics

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us